“The world’s first artificial intelligence (AI)-based protein design COVID-19 vaccine.” It is a modi..
https://www.mk.co.kr/en/it/12068683
Publish Date: 2026-06-08 04:44:00
Source Domain: www.mk.co.kr
-
Artificial Intelligence (AI)-based Protein Design COVID-19 Vaccine: SK Bioscience, through its vaccine “SkyCovid One,” applied AI-based antigen design technology, marking a significant step forward in the development process.
-
AI Across the Vaccine Development Process: AI is being used from Research & Development (R&D) to production and quality control, aiming to shorten the typically long development process (10 to 15 years) of new drugs.
-
Optimization in Production Process: AI is helping optimize production conditions (e.g., temperature, flow rate) to achieve consistency and higher yields, reducing emergency production situations and improving predictability.
-
Enhanced Research & Development Efficiency: Digital twin simulations and machine learning in R&D stage aid in identifying promising hypotheses, aiming to reduce the new drug development period by over 30%.
-
Repetitive Task Automation: In research institutes, AI handles repetitive tasks like data analysis, document preparation, and thesis searches, particularly streamlining the creation of common technical documents (CTD) for product approval applications.
-
Data Utilization for AI Competitiveness: A significant challenge in AI adoption is data: 70% of AI projects involve data preprocessing. SK Bioscience focuses on organizing accumulated data into a form usable by AI, enhancing its competitiveness.
-
AI Agents in Workforce: The company envisions a future where every employee works with multiple AI agents, with goals to have over 100 active by the end of the year, positioning advanced AI integration as a key competitive factor.
